| Literature DB >> 23213273 |
Masahiro Miyake1, Kenji Yamashiro, Hideo Nakanishi, Isao Nakata, Yumiko Akagi-Kurashige, Akitaka Tsujikawa, Muka Moriyama, Kyoko Ohno-Matsui, Manabu Mochizuki, Ryo Yamada, Fumihiko Matsuda, Nagahisa Yoshimura.
Abstract
PURPOSE: The objective of this study was to investigate whether genetic variations in the paired box 6 (PAX6) gene are associated with high myopia in Japanese subjects.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23213273 PMCID: PMC3513191
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Characteristics of the study population.
| Population characteristics | High myopia* | Case | Control | ||
|---|---|---|---|---|---|
| Control 1† | P value | Control 2 | P value | ||
| Patients (n) | 1307 | 333 | 923 | ||
| Age (mean±SD; years) | 57.1±15.0 | 75.2±7.9 | <0.0001‡ | 56.9±11.4 | 0.8549‡ |
| Sex (n) | |||||
| Male | 427 (32.7%) | 124 (37.2%) | 0.05626§ | 363 (39.3%) | 0.0015§ |
| Female | 879 (67.3%) | 198 (59.5%) | 560 (60.7%) | ||
| Axial length (mm±SD) | |||||
| Right eyes | 29.23±1.85 | 22.84±0.81 | NA | ||
| Left eyes | 29.10±1.82 | 22.88±0.78 | NA | ||
| Refraction of the phakic eyes (D) | |||||
| Right eyes | −12.86±4.44 | −0.411±3.15 | NA | ||
| Left eyes | −12.57±4.71 | −0.296±2.77 | NA | ||
* Axial length >26.00 mm in both eyes. † Individuals who underwent cataract surgery and who had an axial length of <25.00 mm in both eyes.‡ Unpaired t test. Compared with the high-myopia group. § Chi-square test. Compared with the high-myopia group. SD: standard deviation, D: diopter, NA: Not applicable.
Genotype counts, associations, and odds ratios in participants with high myopia and control participants.
| Single nucleotide polymorphisms | Genotype | High myopia | Control 1 | Control 2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | n | Nominal p value* | Adjusted p value† | Adjusted OR (95% CI) | n | Nominal p value* | Adjusted P value† | Adjusted OR (95% CI) | ||
| CC | 326 | 90 | 0.61 | 0.26 | 1.12 (0.92-1.38) | 232 | 0.485 | 0.497 | 1.04 (0.93-1.17) | |
| CT | 632 | 156 | 466 | |||||||
| TT | 344 | 87 | 225 | |||||||
| CC | 1052 | 258 | 0.12 | 0.026 | 0.69 (0.49-0.96) | 710 | 0.0153 | 0.0152 | 0.79 (0.66-0.96) | |
| CA | 237 | 68 | 195 | |||||||
| AA | 14 | 7 | 18 | |||||||
| AA | 544 | 142 | 0.33 | 0.78 | 1.03 (0.83-1.29) | 376 | 0.611 | 0.638 | 0.97 (0.86-1.10) | |
| AG | 590 | 155 | 421 | |||||||
| GG | 171 | 34 | 126 | |||||||
* Differences in the observed genotypic distribution were examined by a chi-square test for trend. † Age and sex adjustment were performed based on a logistic regression model. CI: Confidence interval, OR: Odds ratio.
Genotype counts, associations, and odds ratios in patients with high myopia, extreme myopia and pooled control participants.
| SNP | Genotype | Pooled control | High myopia | Extreme myopia | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Genotype frequency p value* | Allele frequency p value* | HWE P value | n | Nominal p value† | Adjusted p value‡ | Adjusted odds ratio (95% confidence interval) | n | Nominal p value† | Adjusted p value‡ | Adjusted odds ratio (95% confidence interval) | |||
| CC | 322 | 0.53 | 0.99 | 0.74 | 326 | 0.44 | 0.343 | 1.06 | 196 | 0.327 | 0.317 | 1.07 | ||
| (C/T) | CT | 622 | 632 | (0.94–1.18) | 397 | (0.94–1.21) | ||||||||
| TT | 312 | 344 | 215 | |||||||||||
| CC | 968 | 0.95 | 0.95 | 0.15 | 1052 | 0.0105 | 0.00445 | 0.78 | 651 | 0.0294 | 0.0165 | 0.78 | ||
| (C/A) | CA | 263 | 237 | (0.65–0.92) | 149 | (0.64–0.95) | ||||||||
| AA | 25 | 14 | 8 | |||||||||||
| AA | 518 | 0.28 | 0.22 | 1 | 544 | 0.99 | 0.834 | 0.99 | 346 | 0.656 | 0.585 | 0.96 | ||
| (A/G) | AG | 576 | 590 | (0.88–1.11) | 359 | (0.84–1.10) | ||||||||
| GG | 160 | 171 | 104 | |||||||||||
* The difference in genotype and allele frequency between control 1 and control 2 were analyzed using a chi-square test. † Differences in the observed genotypic distribution were examined by chi-square test for trend. ‡ Age and sex adjustment were performed based on a logistic regression model. SNP: Single-nucleotide polymorphism, HWE: Hardy–Weinberg equilibrium
Summary of previous reports that evaluated an association between PAX6 and high myopia.
| Author (year) | Definition of cases | Cases | Controls | Reported single-nucleotide polymorphisms* | Remarks | |||
|---|---|---|---|---|---|---|---|---|
| Criteria of high myopia | Affected eye | |||||||
| Tsai et al., 2008 | SE<6 D | Both | 255 | 87 | n.s. | - | - | Significant association of AC- and AG-repeat lengths in the P1 promoter |
| Ng et al., 2009 | SE≤6 D | - | 379 | 349 | n.s. | - | - | |
| Han et al., 2009 | SE<6 D | Both | FBAT† with 164 nuclear family | n.s. | p=0.0011 | n.s. | Significant association in haplotype analysis | |
| Liang et al., 2011 | SE≤6 D | At least one eye | 1083 | 1096 | n.s. | n.s. | n.s. | |
| Jiang et al., 2011 | SE≤8 D | Both | 300 | 300 | n.s. | n.s. | n.s. | |
| SE≤8 D | Both | 299 | 299 | - | n.s. | - | ||
| Current Study | AL≥26 mm | Both | 1307 | 1256 | p=0.0045 | n.s. | n.s. | |
| Tsai et al., 2008 | SE<10 D | Both | 67 | 87 | p<0.001 | - | - | |
| Liang et al., 2011 | SEM≤11 D | At least one eye | 55 | 619 | p=0.0074 | n.s. | n.s. | |
| Current Study | AL≥28 mm | Both | 810 | 1256 | p=0.0165 | n.s. | n.s. | |
* Single-nucleotide polymorphism pairs with r2 ≧ 0.90 in HapMap Phase II are in the same column. † Family-based association test ‡ Although this single-nucleotide polymorphism is not included in HapMap SNP, it is reported to be in strong linkage disequilibrium (r2=0.92) with rs644242. D: diopter, n.s.: Not significant, SE: Spherical equivalent, AL: Axial length.
Figure 1Collaborative effect of CTNND2 rs6885224 and PAX6 rs644242 on high myopia. The odds ratio of each genotype-pairs was calculated adjusting for age and sex. Patients with both the rs644242 AA genotype (non-risk homo) and the rs6885224 TT genotype (non-risk homo) are set as the reference (odds ratio=1.0). The number of subjects with rs6885224 CC and rs644242 CC were 55 in the case group and 42 in the control group, 286 in the case group and 252 in the control group with rs6885224 CT and rs644242 CC, 392 in the case group and 416 in the control group with rs6885224 TT and rs644242 CC, 15 in the case group and nine in the control group with rs6885224 CC and rs644242 CA, 70 in the case group and 78 in the control group with rs6885224 CT and rs644242 CA, 76 in the case group and 108 in the control group with rs6885224 TT and rs644242 CA, three in the case group and nine in the control group with rs6885224 CT and rs644242 AA, and six in the case group and nine in the control group with rs6885224 TT and rs644242 AA.